Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02104505 · ClinicalTrials.gov registry record · Phase 1
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02104505 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 23 participants.
The verdict
NCT02104505, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
To test the hypothesis that gamma tocopherol (vitamin E) supplement inhibits endotoxin induced airways inflammation in allergic asthmatics
Interventions
- DRUG Placebo
- DRUG Gamma Tocopherol 700 mg capsules,
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02104505
The ClinicalTrials.gov registry entry for NCT02104505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02104505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02104505 about?
NCT02104505 is a clinical study titled "Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS". To test the hypothesis that gamma tocopherol (vitamin E) supplement inhibits endotoxin induced airways inflammation in allergic asthmatics
What is the current status of trial NCT02104505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2015-11. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02104505?
The interventions under investigation include: Placebo (DRUG), Gamma Tocopherol 700 mg capsules, (DRUG).
Who is sponsoring clinical trial NCT02104505?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.